Dorian is a preclinical stage biotech company developing Senoblockers, a new class of therapeutics that rejuvenate cells and tissues. The senoblocker technology is based on a breakthrough discovery made by the founders’ at Stanford University unveiling novel pathways crucial for tissue aging (Adorno, Nature 2013). Small molecules targeting these pathways are undergoing preclinical validation in multiple indications, including kidney disease and osteoarthritis. Senoblockers are also effective in improving cellular fitness during cell therapy bio-manufacturing.
Dorian is backed by a number of VCs including Y Combinator, Longevity Fund, Boom Capital, Pacific8 Ventures, StartX Fund and has received $4.5M in undiluted fundings from NIH to support the preclinical development of senoblockers. The team is advised by board members Aya Jakobovits (former CEO of Kite Pharma and founding CEO of NASDAQ-listed Adicet Bio) and Jeff George (former CEO Sandoz and Alcon).
Dorian is backed by a number of VCs including Y Combinator, Longevity Fund, Boom Capital, Pacific8 Ventures, StartX Fund and has received $4.5M in undiluted fundings from NIH to support the preclinical development of senoblockers. The team is advised by board members Aya Jakobovits (former CEO of Kite Pharma and founding CEO of NASDAQ-listed Adicet Bio) and Jeff George (former CEO Sandoz and Alcon).
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
small molecule
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
